To understand tissue architecture, it is necessary to understand both which cell 10 types are present and the physical relationships among them. Single-cell RNA-11 Seq (scRNA-Seq) has made significant progress towards the unbiased and 12 systematic identification of cell populations within a tissue, however, the 13 characterization of their spatial organization within it has been more elusive. The 14 recently introduced 'spatial transcriptomics' method (ST) reveals the spatial 15 pattern of gene expression within a tissue section at a resolution of a thousand 16 100 µm spots across the tissue, each capturing the transcriptomes of multiple 17 cells. Here, we present an approach for the integration of scRNA-Seq and ST data 18 generated from the same sample, and deploy it on primary pancreatic tumors 19 from two patients. Applying our multimodal intersection analysis (MIA), we 20 annotated the distinct micro-environment of each cell type identified by scRNA-21 Seq. We further found that subpopulations of ductal cells, macrophages, 22 dendritic cells, and cancer cells have spatially restricted localizations across the 23 tissue, as well as distinct co-enrichments with other cell types. Our mapping 24 approach provides an efficient framework for the integration of the scRNA-Seq-25 defined subpopulation structure and the ST-defined tissue architecture in any 26 tissue.
INTRODUCTION
Recent technological advances have enabled a view into cancer at unprecedented 30 molecular resolution 1 . Single-cell RNA-sequencing (scRNA-Seq) has emerged as a 31 powerful tool for the unbiased and systematic characterization of the cells present in a 32 given tissue 2-4 . Indeed, the application of scRNA-Seq to patient tumors has uncovered 33 multiple cellular subpopulations and has highlighted intercellular cross-talk within the 34 tumor microenvironment 5-12 . However, due to the necessity of cellular dissociation prior 35 to sequencing of individual cells, the spatial context for each cell is lost, thus limiting 36 insight into the precise spatial organization of the cell types constituting a tumor. 37 38 Methods providing spatially resolved transcriptomic profiling [13] [14] [15] [16] [17] [18] [19] have also been 39 introduced, and these are useful for the integration with scRNA-Seq data. For example, 40 in situ hybridization (ISH) gene expression atlases serve as useful references for 41 cellular localization 20, 21 . Using the ISH atlas as a guide, it is possible to accurately map 42 rare subpopulations using a small subset of genes. Such atlases do not exist for solid 43 tumors though, which have variable tissue architecture and gene expression patterns. 44 Thus, high-throughput and comprehensive mapping of single-cells onto tissue requires 45 robust integration of multiple methods. 46 
47
The spatial transcriptomics (ST) method enables spatially-resolved transcriptomic 48 profiling of tissue sections using spatially barcoded oligo-deoxythymidine (oligo-dT) 49 microarrays, allowing for unbiased mapping of transcripts over entire tissue sections 22 microenvironment (Fig. 1b ). The shared cell types between the patient samples 89 demonstrated strong correlation based on their gene expression profiles, suggesting 90 consistent annotation of clusters across samples (Fig. 1c ). 91 92 To distinguish the PDAC cancer cells from the non-malignant ductal cells and other 93 epithelial cells, we used scRNA-Seq-based copy number variation (CNV) analysis (as 94 performed previously 5 , see Methods). For each identified cell type, we inferred 95 chromosomal amplifications and deletions (with the cells of other clusters as the 96 background) and detected two clusters in PDAC-A and one cluster in PDAC-B that 97 displayed aberrant CNV profiles ( Fig. 1d-e ). Notably, the chromosomal loss along 98 chromosome 6 in both samples and the chromosomal gain on chromosome 7 in the 99 PDAC-B profile is consistent with the most common chromosomal abnormalities seen in 100 PDAC from cytogenetic data 34 . As a negative control, we removed a random subset of 101 ductal cells from the background and inferred the relative CNV profiles of these cells 102 ( Fig. S2a ) and found that these do not show an aberrant CNV profile (Fig. S2a ). The 103 two PDAC-A cancer clustershenceforth, cancer clusters 1 and 2were enriched for 104 expression of either TM4SF1 (cluster 1) or S100A4 (cluster 2), while the PDAC-B 105 cancer cluster was only enriched for TM4SF1 expression ( Fig. S2b ), suggesting 106 similarity between PDAC-A cancer cluster 1 and the PDAC-B cancer cluster. 107 
108
To further validate whether the TM4SF1 and S100A4 expressing populations identified 109 in the scRNA-Seq data represent cancer cell populations, we performed double The samples were then processed for ST analysis, involving cDNA synthesis, 134 amplification by in vitro transcription, library construction, and sequencing 19 . We 135 demultiplexed the sequenced reads and identified their spatial location within the tissue 136 using the ST location-specific barcodes of the array. By our estimation from the H&E 137 images, the ST spots captured approximately 20-70 cells per spot ( Fig. S4 ). We expect 138 these numbers to be highly variable depending on the type of tissue and location within 139 the tissue queried. For example, highly fibrotic tissue regions enriched in connective 140 tissue (therefore, lower cellular content) may not capture many cells in ST, compared to 141 tissue with high cellular density such as the acinus of the pancreas (Fig. S4 ). We 142 detected approximately 2,400 UMIs and approximately 1,000 unique genes per spot for 143 both ST datasets ( Fig. S5a-f ). Other published works using the ST method (particularly 144 on human tissue) report similar statistics for the average number of UMIs per spot 145 (Table S1 ). In both sample datasets, we found that the spatial expression of many 146 dynamically expressed genes matched the annotated histological regions ( Fig. 2c-d ). To integrate the scRNA-Seq and ST datasets, we developed Multimodal Intersection 151 Analysis (MIA). This analysis proceeds by first delineating sets of cell type-specific and 152 tissue region-specific genes and then comparing their patterns of enriched or depleted 153 intersections. In the scRNA-Seq data, we defined the gene sets by identifying for each 154 cell type those genes whose expression is statistically higher in the cells annotated to 155 that cell type in comparison to expression in the remaining cells (P < 10 -5 , two-tailed 156 Student's t-test, see Methods). In parallel, in the ST data we defined sets of genes with 157 specific expression for each spatial region. For this, we first performed principal 158 components analysis (PCA) on the 200 most dynamically expressed genes across all 159 ST spots ( Fig. S5g -h, see Methods). After clustering the spots based on the PC scores 160 (see Methods), we found that the clusters consistently coincided with tissue histological 161 annotations ( Fig. 2e-f and Fig. S5g -h). We then identified genes whose expression is 162 significantly enriched for expression in each region (P < 0.01, two-tailed Student's t-163 test).
165
With the gene sets extracted across the scRNA-Seq and ST modalities, MIA next 166 computes the hypergeometric distribution in order to assess the overlap between each 167 pair of cell type-specific and region-specific gene sets ( Fig. 2g ). As an example, we 168 found that the set of genes enriched for expression in the fibroblasts of PDAC-A 169 overlaps significantly with the set of genes with enriched expression in the cancer 170 region of the ST data ( Fig. 2h , P < 10 -10 ). Thus, while the scRNA-Seq data led to 171 identification of fibroblasts, MIA further revealed that these were enriched in the cancer 172 region, as opposed to the stromal region. This suggests that the transcriptomes 173 identified for the fibroblasts correspond to that of activated fibroblasts 35 (Fig. 2h ). 174 Extending this analysis to all pairs of cell types and tumor regions, we found that the 175 duct epithelium region was mainly enriched with ductal cells, while the pancreatic tissue 176 was enriched with acinar cells and endocrine cells (P < 10 -10 , for all specified 177 enrichments). A similar MIA map was found for the PDAC-B sample ( Fig. 2i ). 178 Interestingly, in PDAC-B the interstitium was enriched for endothelial cells and dendritic 7 cells. These results support the utility of MIA maps to provide spatial and functional 180 annotations for the scRNA-Seq-defined cell populations. As in our cell type analysis, we identified marker genes specific to each ductal 207 subpopulation and determined the enrichment of these ductal subpopulations across 208 the tissue region using MIA. We found that all ductal subpopulations in PDAC-A were 209 enriched in the duct region of the tissue while only the hypoxic and terminal ductal cell 210 populations were significantly enriched in the cancer region (P < 10 -4 , Fig. 3i ). It is 211 possible that the transcriptional phenotypes exhibited by these ductal cells reflect 212 environmental signals from the surrounding tissue; i.e., hypoxic ductal cells may be 213 most enriched in the cancerous region compared to the ducts because this region is 214 more hypoxic than other regions. Additionally, the hypoxic ductal cells also appeared to 215 be depleted in the pancreatic tissue (P < 10 -3 , Fig. 3i ). In contrast, the ductal 216 subpopulations in PDAC-B were all exclusively enriched in the ducts of the tissue (P < 217 10 -4 , Fig. 3j ).
218 219 We also found that the PDAC-A macrophages comprised two subpopulations, one of 220 which expressed IL1B, corresponding to an inflammatory M1 state, 42,43 and the other 221 resembling the M2 alternatively activated state based on its expression of CD163 and 222 MS4A4A 44,45 ( Fig. S7a ). We also found two subpopulations of dendritic cells, one of 223 which expressed higher levels of complement pathway genes and MHC class II (Fig. 224 S7b). When we tested for the enrichment of these subpopulations across the tissue with 225 MIA, we found that the subpopulations of macrophages and dendritic cells appear to 226 have opposite patterns of enrichment across the tissue (Fig. S7b,d) . The M2-like 227 macrophages appeared most enriched in the ducts while the M1 macrophages are 228 more enriched in the stroma and cancer regions ( Fig. S7c ). This result is consistent with 229 the M2-like population being tissue resident, with its location reflecting its endogenous 230 functional location, while the M1-like population localizes specifically to the cancer and 231 stroma regions. For the dendritic cell subpopulations, one subpopulation appeared most 232 enriched in pancreatic tissue, while a second population appeared most enriched in the 233 ducts of the tissue (Fig. S7d ). Based on the MIA maps, it is likely that these 234 subpopulations play unique roles in the tissue based on their differential localization 235 thus highlighting new research directions. In the scRNA-Seq data for the PDAC-A tumor we found two cancer cell populations that 240 appeared to be both genetically and transcriptionally distinct ( Fig. 1b-e ). Although we 241 found both cancer populations to be highly enriched in the corresponding ST cancer 242 region ( Fig. 2d ), we asked whether the two cancer populations co-localized with 243 different cell types within this region. To address this question, we used hierarchical 244 clustering to divide the cancer region into transcriptionally coherent sub-regions ( Fig.   245 4a-b). After defining sets of genes enriched for expression in each sub-region, we again 246 applied our MIA mapping approach to study the overlap between the sub-regions sets 247 and the sets of genes defined above for each cell type/subpopulation from the scRNA- 248 Seq data. In the PDAC-B sample, we characterized two sub-regions within the cancer region and 260 defined a gene set specific to each. In the first sub-region, we found co-enrichment of 261 cancer cells with terminal ductal cells and macrophages, while the second sub-region 262 was enriched for terminal ducts, fibroblasts, and endothelial cells ( Fig. 4d ). Across the 263 two MIA maps, we find consistent mutual exclusion of antigen-presenting ductal cells 264 and the TM4SF1 expressing cancer populations (cancer cluster 1 for PDAC-A), 265 suggesting a possible antagonistic relationship between the immunosuppressive cancer 266 cells and antigen presenting cells. For example, the cancer cells may suppress antigen 267 presentation but cells in the adjacent areas may be able to elicit an inflammatory 268 response functioning as a containment method. We also observed consistent co- perspective offered by the intersection of these two technologies is likely to advance 317 clinical/pathological investigation of tumor tissue beyond typical histological techniques. 318 We imagine that the modern pathologist will be able to move beyond studying cell type-319 specific markers and use the maps created by our approach to perform more precise 320 diagnoses of the cancer stage, type, and history.
322
Despite the potential of this integrated method, there are a number of limitations. First, 323 the current version of the ST array is about 6 x 7 mm in size, consisting of just over 324 1000 spots, with each spot being 100 µm in diameter and 100 µm apart. Thus, the array 325 is neither large enough to cover the entire tissue (in many cases) nor are the spots 326 small enough to provide single-cell resolution. We expect the ST technology to improve 327 in terms of both the number and size of the spots on the array, as well as the technical 328 protocol which would reduce the diffusion of transcripts across spots as much as 329 possible. The process of tissue dissociation necessary for scRNA-Seq has the potential 330 to lead to biases as some cell types may be more amenable to dissociation over others, 331 leading to overrepresentation in the data. Therefore, it is necessary to thoroughly 332 dissociate the tissue for processing in order to gain a full representation of the cell types 333 present in the tissue. Additionally, the tissue dissociated for scRNA-Seq comes from the same biological sample, but is not the same exact tissue used for ST. For reliable 335 mapping of scRNA-Seq identified cell types in the ST data it is crucial for the scRNA- based on its expression profile using a similar approach to that previously described 5,7,9 . 
Selection of genes with population-specific expression patterns based on single-
484 cell RNA-Seq data. To identify marker genes for each cell type or subpopulation, we 485 identified differentially expressed genes as described above (P < 10 -5 , two-tailed 486 Student's t-test; effect size > 0.1, Cohen's d). For each gene with P < 10 -5 , we examined 487 for which cell type the effect size was highest and determined that gene to be specific 488 for this cell type. for 15-20 minutes prior to trimming. ST slide was also placed inside cryostat to keep the 502 slide cold and minimize RNase activity. Sections were cut at 10 µm sections and 503 mounted onto the ST arrays, and stored at -80°C until use, maximum of two weeks. 504 Prior to fixation and staining, the ST array was removed from the -80°C and into an 505 RNase free biosafety hood for 5 minutes to bring to room temperature, followed by 506 warming on a 37°C heat block for 1 minute. Tissue was fixed for 10 minutes with 3.6% 507 formaldehyde in 1X PBS, and subsequently rinsed in 1x PBS. Next, the tissue was 508 dehydrated isopropanol for 1 minute followed by staining with hematoxylin and eosin. 509 Slides were mounted in 65 µl 80% glycerol and bright field images were taken on a 510 Leica SCN400 F whole-slide scanner at 40X resolution. printed onto the array is 100 µm in diameter and 200 µm from the center-to-center, 516 covering an area of 6.2 by 6.6 mm. Spots are printed with approximately 2 x 10 8 517 oligonucleotides containing an 18-mer spatial barcode, a randomized 7-mer UMI, and a 518 poly-20TVN transcript capture region 22 (Fig. 1) . 
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